West China Medical School, Sichuan University, Chengdu, 610041, People's Republic of China.
ACS Nano. 2009 Dec 22;3(12):4080-8. doi: 10.1021/nn900785b.
Honokiol (HK) can efficiently inhibit the growth of tumors. However, its clinical applications have been restricted by its extreme hydrophobicity. We hope to improve its water solubility by nanotechnology. And we wonder whether a novel honokiol nanoparticles-loaded thermosensitive poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) (PEG-PCL-PEG, PECE) hydrogel (HK-hydrogel) could improve the therapeutic efficacy on malignant pleural effusion (MPE). To evaluate the therapeutic effects of HK-hydrogel on MPE, MPE-bearing mice were administered intrapleurally with HK-hydrogel, HK nanoparticles (HK-NP), blank hydrogel, or normal saline (NS) at days 4 and 11 after Lewis lung carcinoma (LLC) cells inoculation, respectively. Pleural tumor foci and survival time were observed, and antiangiogenesis of HK-hydrogel was determined by CD31. Histological analysis and assessment of apoptotic cells were also conducted in tumor tissues. HK-hydrogel reduced the number of pleural tumor foci, while prolonging the survival time of MPE-bearing mice, more effectively, as compared with control groups. In addition, HK-hydrogel successfully inhibited angiogenesis as assessed by CD31 (P < 0.05). Histological analysis of pleural tumors exhibited that HK-hydrogel led to the increased rate of apoptosis. This work is important for the further application of HK-hydrogel in the treatment of MPE.
和厚朴酚(HK)能有效抑制肿瘤生长。然而,其极强的疏水性限制了其在临床上的应用。我们希望通过纳米技术提高其水溶性。我们想知道一种新型的载 honokiol 纳米粒子的温敏性聚乙二醇-聚(ε-己内酯)-聚乙二醇(PEG-PCL-PEG,PECE)水凝胶(HK-水凝胶)是否能提高对恶性胸腔积液(MPE)的治疗效果。为了评估 HK-水凝胶对 MPE 的治疗效果,在 Lewis 肺癌(LLC)细胞接种后第 4 天和第 11 天,分别向 MPE 荷瘤小鼠的胸腔内注射 HK-水凝胶、HK 纳米粒子(HK-NP)、空白水凝胶或生理盐水(NS)。观察胸腔肿瘤灶和生存时间,并通过 CD31 测定 HK-水凝胶的抗血管生成作用。还对肿瘤组织中的组织学分析和凋亡细胞进行了评估。与对照组相比,HK-水凝胶能更有效地减少胸腔肿瘤灶的数量,延长 MPE 荷瘤小鼠的生存时间。此外,CD31 评估表明 HK-水凝胶成功抑制了血管生成(P < 0.05)。胸腔肿瘤的组织学分析表明,HK-水凝胶导致了更高的凋亡率。这项工作对进一步将 HK-水凝胶应用于 MPE 的治疗具有重要意义。